growing a uk cell therapy industry delivering health & wealth, presentation by cell therapy...
DESCRIPTION
Matthew Durdy, Chief Business Officer discusses the role and work of the Cell Therapy CatapultTRANSCRIPT
![Page 1: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/1.jpg)
Catapult is a Technology Strategy Board programme
Growing a UK Cell Therapy Industry Delivering
Health & Wealth
Matthew Durdy, Chief Business Officer December 2013 ct.catapult.org.uk
![Page 2: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/2.jpg)
The Cell Therapy (and Regenerative Medicine) Opportunity
2
*US Market data • http://www.cancer.org/cancer/cancerbasics/economic-impact-of-cancer • http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf • http://www.cdc.gov/heartdisease/facts.htm • http://www.pdf.org/en/parkinson_statistics • http://www.provengehcp.com/FAQs.aspx • http://www.dermagraft.com/about/efficacy/
![Page 3: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/3.jpg)
Why a Catapult?
• Learning
• Excellence
• Leadership
• Efficiency
• Risk taking
3
![Page 4: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/4.jpg)
Assets -Facilities and Teams
• Facilities • 1200 sq m on 12th floor • Capacity for 80-100 people • Clinical research cluster • Global location
• Business Team • Business development • Health economics • Business models
• Translational Labs and Team • Process development • Analytical development • GMP process proving
• Clinical Trial and Regulatory Team
• Regulatory • Clinical operations
4
![Page 5: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/5.jpg)
Management Team and Board
5
Keith Thompson Chief Executive (Director, Scottish National Blood transfusion Service, Serologicals)
Dr Natalie Mount Chief Clinical Officer (Director Pfizer, Neusentis. Cambridge, UCL)
Dr Stephen Ward Chief Operating Officer (Director, Stabilitech, Onyvax. Southampton, Imperial)
Matthew Durdy Chief Business Officer (Director, Aqix, Biotec, CDC. Oxford, Chicago)
Dr John Brown, CBE, FRSE Chairman BTG plc, Acambis, CAT
Professor Marc Turner Non-executive Director Edinburgh, SNBTS
Tim Edwards Non-executive Director Chairman, Bio Industry Association
Professor Michael Whitaker Non-executive Director NE Stem Cell Institute
Dr Zahid Latif Non-executive Director Technology Strategy Board
Nick Higgins Non-executive Director Consort Medical, Intercytec
Professor Johan Hyllner Chief Scientific Officer (Director, Cellectis, Cellartis, Vitrolife)
Headcount: 65 22/11/2013
![Page 6: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/6.jpg)
Catapult is a Technology Strategy Board programme
Catapult Themes Risk
![Page 7: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/7.jpg)
Management of Perceived Risk
Solution Nature Example
Risk?
EU Regulation
Not Understood
Expert Advice
Economics Not Clear Prepare Data
GMP Not done Expert partner
Therapy Not proven Share
7
![Page 8: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/8.jpg)
Catapult is a Technology Strategy Board programme
Catapult Themes Funding
![Page 9: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/9.jpg)
Need
• Patient • Clinician • Payer • Seller
Group • Identity • Quantity • Diagnostic
Product • Substance • Process • Regulation • Information
Tasks • Innovation • Quality • Data
Commercial Development Plan
9
Start Commercial
Development Plan
?
![Page 10: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/10.jpg)
Govt. Support
Medical Charities
Financial Investment
Corporate Venturing
Funding for cell therapy in the UK
10
Commercial Development Plan
![Page 11: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/11.jpg)
Successful commercialization depends on both regulatory approval and optimal market access
Quality Safety Efficacy Comparative Clinical & Cost-Effectiveness; Budget Impact
REGULATORY APPROVAL MARKET ACCESS
11
![Page 12: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/12.jpg)
Lab - Pilot - Scale
Commercial Scale
12
Catapult GMP Proving Lab
Catapult Multi Functional development Pod
Tech t ransfer
![Page 13: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/13.jpg)
Collaboration
1+1 = 3
Client knowledge + Expert capabilities = Better outcome
Partner Project Input
Funding Ratio
TSB Grant
SME £1m 60% £0.6m Catapult £1m 100% £1.0m Total £2m £1.6m
80%
Up to 80% UK Technology Strategy Board Funding available for collaboration with SME
![Page 14: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/14.jpg)
Sharing the outputs and opportunities
14
![Page 15: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/15.jpg)
Partners
• Cooperation on manufacturing platforms
• Project sourcing and funding
• International collaboration
15
![Page 16: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/16.jpg)
Project Examples
16
Large Cap Company
• New delivery device to reduce injection pain
• Share of expertise • Support for in house projects
• Phase 2 clinical trials • Scale up, Assays, Freezing and distribution
of cells
• Manufacturing partner, Regulatory, Clinical trial design and delivery
• Immunomodulation • Regulatory, Clinical trial design, business
models
![Page 17: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/17.jpg)
• Commercial Development Plan
Activities
Proof of Principle • Scientific, clinical, regulatory, commercial
Non-clinical • Safety, toxicology, GMP proving, assays
Clinical • Safety and efficacy, investible data
Platform • Generic issues and large collaborations
17
Suitability
![Page 18: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/18.jpg)
18
Working models and finance
Nature of project Paid for by: Carried out by:
Ownership of outputs Finance
Core Project Catapult Catapult Catapult £70m/ 5 years
Contracted Development
Client Catapult Client £10m/ Per year
Industry Collaboration
Grant or Catapult and partner
Catapult and partner
Outputs shared
£10m/ Per year
![Page 19: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/19.jpg)
Gateway Criteria
![Page 20: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/20.jpg)
Blood
Bone & Cartilage
Cardiovascular
Dermatology/Wound Healing
Diabetes
Gastroenterology
Immunology
Liver
Metabolic
Neurological
Oncology
Ophthalmology
Respiratory
Other
hESC iPS MSC Immune Cell
Other Somatic
Building the portfolio
![Page 21: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/21.jpg)
Outputs
Life changing therapies Investible propositions Industry changing innovation Skilled leaders UK leadership
![Page 22: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/22.jpg)
Summary: The Cell Therapy Catapult
Strong first year of growth Laboratories and teams up and running, 60+ Large and small collaborations Global interaction Industry success is our success
Matthew Durdy [email protected] http://ct.catapult.org.uk Twitter: @CTCatapult
![Page 23: Growing a uk cell therapy industry delivering health & wealth, presentation by Cell Therapy Catapult Chief Business Officer Matthew Durdy](https://reader034.vdocuments.us/reader034/viewer/2022042815/557eb819d8b42a48588b4ca8/html5/thumbnails/23.jpg)
Catapult is a Technology Strategy Board programme
Industry
Cell Therapy Catapult
Investment
Researchers
NHS